US EditionNatco Pharma’s generic Semaglutide set for roll out today
Natco Pharma launches multi-dose generic semaglutide with prices starting at ₹1,290 per month as a lower-cost alternative on first day of patent expiry.
- On Saturday, Natco Pharma launched its Semaglutide injection in multi-dose vials in the domestic market, with outlets reporting the rollout on Mar 20–Mar 21.
- After receiving regulatory clearance in February 2026, NATCO got Central Drugs Standard Control Organisation approval to manufacture and market generic Semaglutide, while Eris Lifesciences last month announced a partnership for commercialisation.
- The product will arrive as branded multi-dose vials called Semanat and Semanfull, with MRPs of �1,290 and �1,750, and Natco says it is the first to offer customised syringes with these vials.
- Natco will commercialise the drug directly and via partners, offering it to third-party co-marketers; this sets direct competition with Novo Nordisk’s Ozempic and Wegovy.
- Given India’s diabetes burden and rising obesity, semaglutide, a GLP-1 receptor agonist indicated for adults with type 2 diabetes, costs approximately Rs. 2,200 monthly, says the source.
12 Articles
12 Articles
Weight Loss Injection For ₹900? 3 Firms Launch Semaglutide, Check Prices
Indian pharmaceutical companies have launched affordable versions of semaglutide injections following a patent expiry, significantly lowering costs for diabetes and weight management treatment and...
aninews.in
Zydus Launches Semaglutide Injection in an Innovative, Reusable Multi-Dose Pen Device in India
Ahmedabad (Gujarat) [India], March 21: Zydus Lifesciences Limited (including its subsidiaries, hereafter referred to as "Zydus"), an innovation-led global lifesciences company, has launched Semaglutide Injection under the brand names - SEMAGLYNTM, MASHEMATM and ALTERMETM, upon patent expiry in India. The Drug Controller General of India (DCGI) had earlier provided its approval for manufacturing and marketing Semaglutide injection for the treatme…
Cheaper Weight-Loss Drugs In India: A Big Shift In Fight Against ‘Diabesity’ - PUNE PULSE
With patent expiry opening doors for affordable medicines, experts say access will improve but caution against misuse India is entering a major turning point in the treatment of diabetes and obesity, often referred to together as ‘diabesity’. The expiry of a key drug patent has paved the way for cheaper weight-loss and diabetes medicines, potentially
Coverage Details
Bias Distribution
- 80% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
